Clinical trials: Stereotactic Radiotherapy
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Primary Central Nervous System Diffusing Large Cell Lymphoma
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma.
- Trial name
- NCT07007611
- Volunteers
- 76 people
- Sponsor
- jiahong Deng
Brain Neoplasms, Adult, Malignant
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses.
- Trial name
- SRS (NCT02645487)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypertrophic Obstructive Cardiomyopathy
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing…
- Trial name
- SELECT (NCT04686487)
- Testing
- stereotactic ablative radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non-small Cell Lung Cancer Stage I
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy…
- Trial name
- NCT04271384
- Testing
- nivolumab
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Hospital Israelita Albert Einstein
Oligometastatic Renal Cell Carcinoma
SAbR For Oligometastatic Renal Cell Carcinoma
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy.
- Trial name
- NCT02956798
- Testing
- Stereotactic ablative body radiation (SABR)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Melanoma, Metastatic Malignant Neoplasm in the Spine
Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
This pilot clinical trial studies adaptive staged stereotactic body radiation therapy (SBRT) in treating patients with spinal metastases that cannot be removed by surgery.
- Conditions
- Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma
- Trial name
- NCT02527304
- Testing
- Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Albert Einstein College of Medicine
Spinal Metastases
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS.
- Trial name
- NCT06173401
- Testing
- Single-fraction spine SRS, Multi-fraction spine SRS
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Stanford University
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer
This is a prospective, multicenter, Phase II study aimed at defining the activity and safety of SBRT in MPR-OC. Clinical and imaging data as well as SBRT parameters would be analyzed with the aim to identify potential predictors…
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Oligometastatic Disease
- Trial name
- MITO-RT3/RAD (NCT04593381)
- Testing
- Stereotactic body radiotherapy
- Where
- 14 sites in Italy
- Volunteers
- 376 people
- Sponsor
- Gemelli Molise Hospital
Prostate Cancer
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer.
- Trial name
- NCT04552509
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Linda Chan, MD
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic body radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00087438
- Testing
- stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma…
- Conditions
- Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05830058
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Brain Metastases
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic…
- Trial name
- NCT06649058
- Testing
- Systemic Therapy, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC), Macrovascular Invasion
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
- Conditions
- Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
- Trial name
- MacroTrans (NCT06725121)
- Testing
- Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose…
- Trial name
- NCT02781506
- Testing
- Nivolumab, SAbR
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Sarcoma, Metastatic Disease
Stereotactic Radiation Therapy for Pediatric Sarcomas
The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically…
- Conditions
- Sarcoma, Metastatic Disease, Bony Sites
- Trial name
- NCT01763970
- Testing
- SBRT
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiotherapy
Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer
The purpose of this study is to development of more effective treatment tactics of the stereotactic radiotherapy and radiosurgery alone and together with classic radiation therapy in primary inoperabel solid tumors and…
- Trial name
- ESRTSPIOC (NCT03461822)
- Where
- Azerbaijan
- Volunteers
- 400 people
- Sponsor
- The National Center of Oncology, Azerbaijan
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Brain Metastases, Non-small Cell Lung Cancer
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis.
- Trial name
- NCT06020066
- Testing
- EGFR-TK Inhibitor, Stereotactic radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Fudan University
Microsatellite Stable Metastatic Colorectal Cancer
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.
- Trial name
- iPULSAR-CRC (NCT06841159)
- Testing
- Ultra-fractionated radiation therapy, Sintilimab, Standard systemic therapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Fudan University